Weekly PhD Newsletter | SIGN UP NOW Weekly PhD Newsletter | SIGN UP NOW

alzheimer PhD Projects, Programmes & Scholarships

We have 63 alzheimer PhD Projects, Programmes & Scholarships

Discipline

Discipline

All disciplines

Location

Location

All locations

Institution

Institution

All Institutions

PhD Type

PhD Type

All PhD Types

Funding

Funding

All Funding


We have 63 alzheimer PhD Projects, Programmes & Scholarships

PhD saved successfully

ERK5 MAPK signalling in Alzheimer’s disease

  Research Group: Pharmacology and Experimental Therapeutics
Neurodegenerative diseases have devastating effects on individuals’ lives and our society, with no effective treatments available. Read more

Can transcranial ultrasound be used to change the course of neurodegenerative disease?

White matter impairments are a major component of various neurodegenerative diseases, including Alzheimer’s disease(1,2). White matter is composed of neuronal axons and their encasing myelin; a lipid-rich material produced by the oligodendroglia. Read more

AI and Machine Learning for the diagnosis and monitoring of Parkinson’s and Alzheimer’s disease

The School has long-standing research collaborations with hospitals and medical centres worldwide developing new approaches to the diagnosis and monitoring of neurological conditions, including Parkinson’s and Alzheimer’s. Read more

Investigating the role of endothelial cells in myelin damage in Alzheimer's diseases using iPSC-derived model

Alzheimer’s disease (AD) affects around 50 million people globally with no cure. Apart from well-known neuronal loss, myelin abnormalities in brain have been recently detected from early stage of AD. Read more

4 Year PhD with Integrated MSc in Neuroscience: ApoE-ε4 induced blood-brain barrier dysfunction in Alzheimer’s disease

Background. Blood-brain barrier dysfunction in Alzheimer’s Disease (AD). The blood-brain barrier (BBB) is formed by a continuous layer of cerebral endothelial cells held together by tight junction proteins (TJP), which restrict the movement of molecules. Read more
Last chance to apply

Development of a multiplex diagnostic test for Alzheimer’s Disease

  Research Group: Medicine
Alzheimer’s disease (AD) is the most common cause of dementia worldwide. Current tools for monitoring AD pathology include neuroimaging biomarkers using MRI or PET and CSF biomarkers. Read more

Generating a disease model for Alzheimer's Disease in non-human primates

Our lab is interested in understanding and treating a devastating neurodegenerative disorder, Alzheimer’s Disease (AD), in particular aspects relating to develop appropriate disease models for AD. Read more

Neuroinflammation, glial cell dysfunction & neurodegenerative diseases

Neurodegenerative disorders, such as Alzheimer’s disease, are often associated with chronic neuroinflammation and glial cell dysfunction that acts to exacerbate neuronal damage and loss of synapses. Read more

The breakdown of neurovascular coupling in the diseased state specifically Epilepsy and Alzheimer’s disease

Epilepsy is the most common neurological condition in the UK, affecting 1 – 2 % of the population. Epilepsies often involve only a small area of the brain - the epileptic focus – and the abnormal activity can propagate out from there. Read more

3D-Printing of implantable devices for the treatment of chronic conditions

Non-adherence to treatment costs the NHS more than £500M each year. Adherence is especially important when treating patients with chronic conditions that require lifetime pharmacological treatment, such as schizophrenia, Parkinson’s disease, HIV and Alzheimer’s disease. Read more

Exploring how Natural Language Processing (NLP) can help with the diagnosis of dementia

  Research Group: Visual Computing
The Alzheimer’s Society acknowledges the COVID-19 pandemic led to a significant decrease in dementia diagnosis rates from 67.6% in February 2020 to 63.5% in June 2020. Read more

Understanding the heterogeneity of pathology in dementia with Lewy bodies to aid the interpretation of biomarkers

The primary pathology of dementia with Lewy bodies (DLB) is alpha-synuclein, however multiple studies have demonstrated that Alzheimer’s disease (AD) related pathologies (tau and beta amyloid) play an important role in disease progression driving spread of pathology and accelerating cognitive decline. Read more

Filtering Results